Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vishakha Mhase"'
Autor:
S. Pawar, Rutuja Bhave, Raja Dhasarathan, Mahesh Ukade, Vineet Datta, Chirantan Bose, Harshal Bodke, Ajay Srinivasan, Stefan Schuster, Dadasaheb Akolkar, Shabista Khan, Cynthe Sims, Darshana Patil, Jatinder Bhatia, Vishakha Mhase, Sanket Patil, Rajan Datar, Sachin Apurwa, Samruddhi Raut
Publikováno v:
Cancer Research. 81:PS4-36
Background: Despite the development of Checkpoint Inhibitor Treatments (Immunotherapy) and Targeted anticancer agents, cytotoxic (chemotherapy) agents remain the mainstay of breast cancer treatments. However, treatment failure is often encountered in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40c5256e99a56418ca3a337eb47941e
https://doi.org/10.1158/1538-7445.sabcs20-ps4-36
https://doi.org/10.1158/1538-7445.sabcs20-ps4-36
Autor:
Cynthe Sims, Vineet Datta, Dadasaheb Akolkar, Viwek Mane, Madhavi Apastamb, Sachin Apurwa, Ajay Srinivasan, Ashok Gawai, Tim Crook, Revati Patil, Sanket Patil, Rajan Datar, Vishakha Mhase
Publikováno v:
Cancer Research. 80:P6-10
Background: Chemoresistance in cancer cells is the underlying reason for treatment failure. Real-time monitoring of chemoresistance and response (CRR) is a fundamental but unmet prerequisite of precision oncology. Repetitive invasive biopsies to obta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::681b1dd60500e19edf84a55eccd83758
https://doi.org/10.1158/1538-7445.sabcs19-p6-10-11
https://doi.org/10.1158/1538-7445.sabcs19-p6-10-11
Autor:
Sewanti Limaye, Rajan Datar, S. Pawar, Ashok Gawai, Darshana Patil, Cynthe Sims, Stefan Schuster, Tim Crook, Vineet Datta, Raymond L. Page, Ajay Srinivasan, Sachin Apurwa, Vishakha Mhase, Dadasaheb Akolkar, Harshal Bodke, Sanket Patil
Publikováno v:
Journal of Clinical Oncology. 38:3525-3525
3525 Background: Despite the development of targeted therapy agents and immune checkpoint inhibitors (ICI), cytotoxic anticancer agents remain the mainstay of treatment in several solid organ cancers. However, instances of innate and acquired resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::051c679b7e398ead692eda4921d00783
https://doi.org/10.1200/jco.2020.38.15_suppl.3525
https://doi.org/10.1200/jco.2020.38.15_suppl.3525
Autor:
Darshana Patil, Tim Crook, Sewanti Limaye, Vineet Datta, Raymond L. Page, Revati Patil, Vishakha Mhase, Shabista Khan, Cynthe Sims, Rajan Datar, Stefan Schuster, Sachin Apurwa, Dadasaheb Akolkar, Ajay Srinivasan, Sanket Patil
Publikováno v:
Journal of Clinical Oncology. 38:194-194
194 Background: Resistance to combination regimens of fluorouracil, oxaliplatin and irinotecan are commonly observed in Colorectal cancers (CRC). There are presently no viable approaches for ‘real-time’ monitoring of innate and acquired chemoresi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1938755a108fc59f91e6fc2f2bd8212b
https://doi.org/10.1200/jco.2020.38.4_suppl.194
https://doi.org/10.1200/jco.2020.38.4_suppl.194
Autor:
Stefan Schuster, Revati Patil, Sanket Patil, Jatinder Bhatia, Pooja Fulmali, Vineet Datta, Vishakha Mhase, Pradip Devhare, Ajay Srinivasan, Rajan Datar, Dadasaheb Akolkar
Publikováno v:
Neuro Oncol
Survival of high-grade glioma patients remains dismal due to onset of resistance to even the limited systemic treatment option currently available. Except for indirect prediction of alkylating agent Temozolomide response through MGMT promotor methyla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b48d77069349c7a5e8a08e4210d609
https://doi.org/10.1093/neuonc/noz175.567
https://doi.org/10.1093/neuonc/noz175.567